In the old days, companies like Apple and Amazon went public early to access cash to grow. These days, soon-to-be-public ...

In this podcast, Motley Fool analysts Emily Flippen and Sanmeet Deo and contirubtor Jason Hall break down why the IPO market took off in 2025, which new listings may look like future Rule Breakers, ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest. IPO’s portfolio is heavily growth-oriented, with 94% SMID-cap exposure and ...

If all three went public it could “conceivably create more value than all VC-backed IPOs since 2000 have collectively.” ...

Last year turned out to be one of the best years for initial public offerings (IPOs) since 2014. In 2025, the U.S. had 353 IPOs, with 210 operating company IPOs, and $70 billion in capital raised.

In 2025, the initial public offering (IPO) market continued to rebound from the 2022 and 2023 slump. For the second year in a row, markets saw more IPOs, more special purpose acquisition companies ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. Biotech listings saw their heyday in the middle of the COVID-19 pandemic, when an incredible 87 U.S.-based drug developers ...

Forbes contributors publish independent expert analyses and insights. Jim Osman is a finance expert with over 30 years of experience. Having spent over 35 years in the financial markets, I have ...